Use to detect and quantitate PML-RARA fusion transcripts in patients with acute promyelocytic leukemia. Use to monitor minimal residual disease and assess the risk of disease relapse.
Reverse Transcription Polymerase Chain Reaction
New York DOH Approval Status
Whole blood or bone marrow in lavender (EDTA).
Whole Blood: Transport 5 mL whole blood. (Min: 3 mL)
Bone Marrow: Transport 3 mL bone marrow. (Min: 1 mL)
Refrigerate immediately. Specimens must be received within 48 hours of collection due to lability of RNA.
Whole Blood and Bone Marrow: CRITICAL REFRIGERATED. Separate specimens must be submitted when multiple tests are ordered.
Serum, plasma, ambient or frozen bone marrow or whole blood, CSF, or FFPE tissue. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed or clotted specimens.
Ambient whole blood and ambient bone marrow specimens past 7 days will be cancelled. Refrigerated whole blood or bone marrow past 7 days will be canceled.
Ambient: Unacceptable; Refrigerated: 48 hours; Frozen: Unacceptable
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2002874||PML-RARA Translocation Quant||21785-1|
|3003498||PML-RARA Translocation Source||66746-9|
- AMPL' APL
- APL MRD
- APL Post-consolidation therapy testing
- PML-RARA fusion types, A, B, B variant
- PML-RARA long, short, variable types
- PML-RARA S, L, V forms
- PML_RARA fusion types
- Quantitative PML